Belle Schimibao will soon complete the acquisition of $ 4.1 billion!

Source: Yaozhi.com/Forest

On August 16, BMS announced that it had received a merger license from Federal Cartel Office in Germany and was expected to complete the transaction tomorrow. Earlier this summer, the pharmaceutical giant reached a transaction to acquire all the issued Turn Point shares at a price of $ 76 ($ 4.1 billion) per share.

Turning Point Therapeutics is a precise oncology company at the clinical stage. It has a series of research drugs that aim to target the most common mutations related to cancer. At present, the company's main assets are the next generation of potential heavy -duty drug tyrosine oscillatase inhibitors (TKI), non -small cell lung cancer (NSCLC), and drugs for other advanced physical tumor ROS1 and NTRK.

The product lines of Turning Point Therapeutics include Repotrectinib, TPX-0022, TPX-0046, and the next-generation ALK inhibitor TPS-0131.

Repotrectinib for ROS1 -positive NSCLC and NTRK fusion positive physical tumor indications. It has obtained the FDA awarded ROS1 -positive metastatic NSCLC for the treatment of the first -line treatment of ROS1 inhibitors. ROS1 positive metastatic NSCLC's breakthrough therapy for ROS1 -containing chemotherapy with platinum -containing chemotherapy is received. It is estimated that in the second half of 2023, RepotRctinib may be approved in the United States, and peak sales may reach US $ 10-15 billion.

In July 2020, Ding Ding Medicine obtained the exclusive development and commercialization of REPOTRECTINIB in Greater China with an amount of over 170 million US dollars.中中国患者的主要数据，结果显示，在既往未接受过ROS1-TKI治疗的队列（n=71）中，ORR为79%，4例（6%）患者获得完全缓解（CR），52例（ 73%) Patients were partially relieved, and 11 of the 11 patients from China were 91%.

With the completion of the transaction, Belief Schimi Bao will compete with Pfizer's Xalkori and Roche's Rozlytrek in ROS1 -positive non -small cell lung cancer.

Disclaimer: The integration of this article does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -